Company intelligence / Profile preview
Aeonvital Biomedicine Research Company Ltd.
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Aeonvital Biomedicine has one product (ReT01 ACT) in Phase 1 clinical trials for advanced solid tumors. A single-armed, open Phase I study of ReT01 ACT injection began recruiting in April 2024 to evaluate safety and tolerance in patients with advanced solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Biological productsTIL therapyCancer immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Aeonvital Biomedicine Research Company Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aeonvital Biomedicine Research Company Ltd..